Clinical Edge Journal Scan

Increased risk for second primary lung cancer in breast cancer patients


 

Key clinical point: Women with breast cancer (BC), especially those with low-grade malignancy, had a greater risk of developing a second primary lung cancer.

Major finding: The risk for second primary lung cancer was 1.4 (95% CI 1.25-1.55) times higher in patients with BC compared with the general population, with estrogen receptor-negative BC, low Ki67 levels, and no lymph node metastasis (all P = .01) being significant risk factors. Among patients who developed lung cancer, the rate of epidermal growth factor receptor mutation was high (78.5%).

Study details : This study analyzed the data of 9179 patients with BC, of which 6512 patients had undergone diagnostic chest computed tomography and 55 patients were diagnosed with a second primary lung cancer.

Disclosures: This study was supported by the National Key Research and Development Program of China and other sources. The authors declared no conflicts of interest.

Source: Zeng T et al. High rate of epidermal growth factor receptor-mutated primary lung cancer in patients with primary breast cancer. Front Oncol. 2022;12:985734 (Oct 13). Doi: 10.3389/fonc.2022.985734

Recommended Reading

How AI is, or will soon be, relevant in radiation oncology
MDedge Hematology and Oncology
Novel vaccine approach halts disease after 23 years of breast cancer
MDedge Hematology and Oncology
Personalized breast screening a step closer to reality
MDedge Hematology and Oncology
Exceptional responders to neoadjuvant systemic therapy may omit breast cancer surgery
MDedge Hematology and Oncology
Radiotherapy increases risk for thoracic angiosarcoma in breast cancer survivors
MDedge Hematology and Oncology
gBRCA1/2pv-associated HER2− early BC: Adjuvant olaparib improves OS in the long run
MDedge Hematology and Oncology
Late detection and worse outcomes in invasive lobular vs ductal carcinomas of the breast
MDedge Hematology and Oncology
Invasive BC: Severe chemotherapy-induced peripheral neuropathy with nab-paclitaxel
MDedge Hematology and Oncology
Proton-pump-inhibitors can be used with ribociclib in metastatic BC
MDedge Hematology and Oncology
Elevated breast cancer risk in thyroid cancer survivors partly due to I-131 treatment
MDedge Hematology and Oncology